Loading clinical trials...
Loading clinical trials...
Post-Licensure Observational Study of the Long-term Effectiveness of ZOSTAVAX™
This study will describe the impact of vaccination with ZOSTAVAX™ on the epidemiology of herpes zoster (HZ) in a cohort of vaccinated participants 50 years or age or older, compared to a cohort of unvaccinated participants.
Age
50 - No limit years
Sex
ALL
Healthy Volunteers
Yes
Start Date
May 15, 2012
Primary Completion Date
October 16, 2020
Completion Date
October 16, 2020
Last Updated
July 14, 2022
1,505,647
ACTUAL participants
ZOSTAVAX™
BIOLOGICAL
Lead Sponsor
Merck Sharp & Dohme LLC
Collaborators
NCT07378059
NCT06932523
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06903078